Compare Stocks

Ionis Pharmaceuticals Inc. (IONS) is scheduled to report 3rd quarter earnings on 11/09/2026. Regarding Q3 estimates, Wall Street analysts expect Ionis Pharmaceuticals Inc. to post earnings of -$1.23 per share.

Ionis Pharmaceuticals Inc. (IONS) is scheduled to report 3rd quarter earnings on 11/04/2026. Regarding Q3 estimates, Wall Street analysts expect Ionis Pharmaceuticals Inc. to post earnings of -$1.22 per share.

Citi analyst Eric Joseph maintained a Buy rating on Ionis Pharmaceuticals yesterday and set a price target of $100.00. Eric Joseph has given his Buy rating due to a combination

The latest update is out from Ionis Pharmaceuticals ( ($IONS) ). On October 23, 2026, Ionis’ partner Roche reported late‑breaking Phase 3 data from the ongoing IMAgINATION trial in adults

Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating

The major averages were broadly lower near noon amid renewed concerns over AI spending and an increase in oil prices. Meta shares are sliding despite strong revenue growth as investors

Ionis Pharmaceuticals (IONS) was granted FDA orphan designation for a treatment of Dravet syndrome, according to a post on the agency’s website. Published first on TheFly – the ultimate source

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Ionis Pharmaceuticals ( ($IONS) ) just unveiled an update. On October 20, 2026, Ionis reported that partner GSK had secured U.S. FDA approval for HIBSAGO (bepirovirsen), a first-in-class RNA-targeted therapy

Ionis Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebowitz from BMO Capital upgraded the rating on the stock to a Buy and